Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 29 May 2018
At a glance
- Drugs Dexamethasone (Primary) ; Elotuzumab (Primary) ; Nivolumab (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 22 May 2018 Status changed from recruiting to discontinued due to safety reasons.
- 09 Sep 2017 Status changed from not yet recruiting to recruiting.
- 20 Jan 2017 New trial record